a favorable trendP = .10
Among well-established predictors of ICI outcomes, 31 - 35 EBV status was not significantly associated with overall survival in patients treated with nivolumab plus chemotherapy although a favorable trend was observed (hazard ratio [HR], 3.86e-08 [95% CI, 0 to infinity]; log-rank test P = .10; Fig 3 A).